ReNeuron Group (RENE): Re-initiation - Rebranding in Exosome Targeted Drug Delivery
LONDON, UK / ACCESSWIRE / November 3, 2022 / ReNeuron is a UK-based stem cell research company now strategically re-focused on the development of its exosome drug delivery technologies. Recent encouraging preclinical proof-of-concept data demonstrated the potential of ReNeuron's exosomes to deliver complex therapeutic payloads with high tissue specificity. Drug delivery remains a major challenge in both central nervous system and cell and gene drug development, and we view these as key markets for ReNeuron to offer differentiation. Positive preclinical data have led to the signing of substantial licensing deals within the exosome market which, if acquired, would represent a significant catalyst for the share price. To date, the company has established seven discovery stage collaborations with pharma, biotech and academic institutions, through which its proprietary exosome platform is being investigated for application in targeted drug delivery. We value ReNeuron at £47.3m or 83p per share.
We value ReNeuron at £47.3m or 83p per share, based on a risk-adjusted net present value of two assumed preclinical exosome programmes and the out-licensed cortex stem cell therapy programme to Fosun Pharma in stroke disability. At end-March 2022, the company had a gross cash position of £14.5m, which we estimate will fund operations to end FY Q124 (June 2023).
Click here to view the full report or here to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website www.edisongroup.com
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Soo Romanoff +44 (0)20 3077 5700 healthcare@edisongroup.com
Dr Adam McCarter +44 (0)20 3077 5700 healthcare@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited
View source version on accesswire.com:
https://www.accesswire.com/723476/ReNeuron-Group-RENE-Re-initiation--Rebranding-in-Exosome-Targeted-Drug-Delivery
